Newsletter | November 20, 2023

11.20.23 -- SOPs For Human Error Prevention In Manufacturing


Human Performance Theories And SOPs: Human Error Prevention In Manufacturing

This article explores how to create, review, and train on SOPs, as well as how manufacturing and quality teams can collaborate to improve oversight, all with human error prevention in mind.

The Importance Of Vendor Selection

Regarding vendor selection in support of allogeneic CAR-T therapy specifically, Gregory Opiteck, Ph.D., VP head of translational sciences at Allogene Therapeutics, covers top challenges, best practices, and expectations for the short term.


Packaging And Containment: Get Your Products To Market Faster

Learn more about why focusing on packaging solutions early on can keep development on track, help you meet milestones, and get your product to market faster.

Top 6 Tips To Speed Up Manufacturing Your Product

Managing the manufacturing process for cell and gene therapy products can be a significant challenge. Delays can affect capacity, resource planning, and the path to product commercialization.

Prioritizing Speed In Drug Therapy Development And Moving Fast Safely

Sponsors face pressure to balance speed, cost, and quality. Examine considerations to help you accelerate the delivery of transformative therapies while maintaining safety and upholding efficacy standards.

Combining Gene Therapies, Carrier Systems, And Medical Devices

Drug delivery is one of the most significant obstacles to advancing gene therapies. Examine the opportunities for success in combining novel medical devices to improve delivery of gene therapies.

Challenges Of Scaling Up Cell Therapy To New Geographies

Cell therapy has emerged as one of the most promising disruptive innovations in the pharma industry, but companies developing cell therapies have not been able to take full advantage of its massive potential.

The CDMO Value Proposition For Your Autologous Cell Therapy

This panel session features a decade-long story of partnership in bringing two life-changing gene therapies to market successfully in 2022.


A Global CDMO Fully Dedicated To Cell And Gene Therapies

The Future Of Reimbursement For Cell & Gene Therapies

Sonexus Access And Patient Support: Supporting Patients At Every Step

Advancing Vaccines From Preclinical Development To Commercial Supply

CGT Solutions Brochure

Connect With Cell & Gene: